Stable Gastric Pentadecapeptide BPC 157 and Striated, Smooth, and Heart Muscle.
Staresinic. Mario M; Japjec. Mladen M; Vranes. Hrvoje H; Prtoric. Andreja A; Zizek. Helena H; Krezic. Ivan I; Gojkovic. Slaven S; Smoday. Ivan Maria IM; Oroz. Katarina K; Staresinic. Eva E; Dretar. Vilim V; Yago. Haidi H; Milavic. Marija M; Sikiric. Suncana S; Lovric. Eva E; Batelja Vuletic. Lovorka L; Simeon. Paris P; Dobric. Ivan I; Strbe. Sanja S; Kokot. Antonio A; Vlainic. Josipa J; Blagaic. Alenka Boban AB; Skrtic. Anita A; Seiwerth. Sven S; Sikiric. Predrag P
Key Findings
- BPC‑157 dramatically repaired severed myotendinous junctions in rats, restoring muscle‑tendon function.
- The peptide was effective via several routes (intraperitoneal injection, oral in water, topical) at ultra‑low doses (µg‑ng range).
- Broad cytoprotective effects were reported across many injury models (vascular, neural, toxin‑induced, heart and smooth muscle dysfunction).
Practical Outcomes
- For biohackers, BPC‑157 looks promising as a low‑dose, multi‑route supplement for muscle‑tendon recovery, but human data are missing. If experimenting, start with very small oral or sub‑Q doses (microgram range) and watch for any side effects. Expect that most of the claimed benefits are still unproven in people.
Summary
In rats, the peptide BPC‑157 helped heal completely cut muscle‑tendon connections and a range of other tissue injuries. It worked whether given by injection, in drinking water, or applied directly to the wound, and seemed safe even at very low micro‑ to nanogram doses. The authors also claim it protects the heart, smooth muscle and many other injury models, but all data are from animal studies.
Abstract
First, we review the definitively severed myotendinous junction and recovery by the cytoprotective stable gastric pentadecapeptide BPC 157 therapy, its healing that might combine both transected and detached tendon and transected muscle, ligament and bone injuries, applied alone, as native peptide therapy, effective in rat injury, given intraperitoneally or in drinking water or topically, at the site of injury. As a follow up, we reviewed that with the BPC 157 therapy, its cytoprotective ability to organize simultaneous healing of different tissues of and full recovery of the myotendinous junction might represent the particular muscle therapy against distinctive etiopathology muscle disabilities and weakness. In this, BPC 157 therapy might recover many of muscle disabilities (i.e., succinylcholine, vascular occlusion, spinal cord compression, stroke, traumatic brain injury, severe electrolyte disturbances, neurotoxins, neuroleptics, alcohol, serotonin syndrome and NO-system blockade and tumor-cachexia). These might provide practical realization of the multimodal muscle-axis impact able to react depending on the condition and the given agent(s) and the symptoms distinctively related to the prime injurious cause symptoms in the wide healing concept, the concept of cytoprotection, in particular. Further, the BPC 157 therapy might be the recovery for the disabled heart functioning, and disabled smooth muscle functioning (various sphincters function recovery). Finally, BPC 157, native and stable in human gastric juice, might be a prototype of anti-ulcer cytoprotective peptide for the muscle therapy with high curing potential (very safe profile (lethal dose not achieved), with suited wide effective range (µg-ng regimens) and ways of application).
Study Information
pubmed
2022
2022-12-12T00:00:00.000Z
10.3390/biomedicines10123221
14
170